We are excited to announce that Eagle IP has been named as the winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026.

The LSPN Awards recognize outstanding achievement, innovation, and leadership within the life sciences intellectual property community. The Cross-Border Collaboration Partner of the Year Award honors the non-US law firm that has demonstrated exceptional partnership with US law firms and life sciences companies through superior cross-jurisdictional expertise, strategic counsel, and seamless collaboration.

This award underscores the strength of our team’s commitment to delivering sophisticated, high-quality intellectual property services that effectively bridge Greater China and global markets. We remain dedicated to serving as a trusted partner to our US and international colleagues in advancing life sciences innovation through strategic patent protection and portfolio management.

Our President and Managing Director Ms. Jennifer Che traveled to Boston last week to accept the award on behalf of our entire team, as well as to speak at the LSPN two-day conference which preceded the awards ceremony.

We are truly honored to be named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026! This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration.


Explore the full list of winners from this year’s LSPN Awards USA: https://awards.newton.media/lspnawards2026/en/page/2026-winners

我們過去活動

Recommended Insights

Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

2021年4月29日
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents

2026年1月29日
Each year the CNIPA publishes its Top Ten Patent Re-examination and Invalidation Cases for the previous year. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Today we’ll be sharing about one of the Top 10 Invalidation Cases in 2024 involving Microsoft (China) Co., Ltd. […]
Top crossarrow-right